Editorials in The New York Times and The Wall Street Journal say the resignation of FDA commissioner Lester Crawford gives the Bush administration the opportunity to put effective leadership in place at the agency, but the papers disagree on who should be the new leader. The Times said the interim choice, Dr. Andrew von Eschenbach, has received "mixed reviews" during his time at the National Cancer Institute, while the Journal said he understands the need to "speed good therapies to patients."

Related Summaries